 
        





| Catalog No. | HS870046 | 
|---|---|
| Species reactivity | Human | 
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo | 
| Host species | Human | 
| Isotype | IgG4-kappa | 
| Expression system | Mammalian Cells | 
| Clonality | Monoclonal | 
| Target | Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279 | 
| Endotoxin level | Please contact the lab for this information. | 
| Purity | >95% purity as determined by SDS-PAGE. | 
| Purification | Protein A/G purified from cell culture supernatant. | 
| Accession | Q15116 | 
| Form | Liquid | 
| Storage buffer | 0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. | 
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. | 
| Alternate Names | JNJ-63723283, 2050478-92-5 | 
| Background | Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. PD-1 is a negative regulator of immune activation that is considered a foundational target within the immuno-oncology market. • The blockade of immune checkpoints in cancer immunotherapy., PMID:22437870 • PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations., PMID:30888929 • The diverse functions of the PD1 inhibitory pathway., PMID:28990585 • PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy., PMID:30191996 • Immune Checkpoint Blockade in Cancer Therapy., PMID:25605845 • PD-1 expression and clinical PD-1 blockade in B-cell lymphomas., PMID:29118007 • Overcoming T cell exhaustion in infection and cancer., PMID:25797516 • Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker., PMID:32875727 • Tumor Mutational Burden and Response Rate to PD-1 Inhibition., PMID:29262275 • PD-L1., PMID:29097600 | 
| Note | For research use only. Not suitable for clinical or therapeutic use. | 

SEC-HPLC detection for Research Grade Cetrelimab.

Detects Human CD279/PDCD1/PD1 in indirect ELISAs.

SDS-PAGE for Research Grade Cetrelimab




Contact us for custom quotes, bulk requests and any other issues.
Mail: support@abinScience.com






+86-027-65523339
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
 
                 中文
 中文 English
 English